SCHEMBL2910339

SCHEMBL2910339

COc1ccc(C(Nc2cccc(C(=O)OC(C)(C)C)c2)c2cccnc2)cc1NC(=O)C(C)C

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.42
HTT P42858 2/20 0.42
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
LMNA P02545 2/20 0.40
USP2 O75604 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TP53 P04637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MAPT P10636 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ALPL P05186 1/20 0.39
RAF1 P04049 1/20 0.39
AHR P35869 1/20 0.39
KDM4E B2RXH2 1/20 0.38
CSF1R P07333 3/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2910933 0.83 PDE4D (0.40) HTTMEN1KMT2ALMNAALDH1A1
SCHEMBL2908203 0.82 MKNK1 (0.45) MAPK1HTTMEN1KMT2ALMNA
SCHEMBL2935248 0.76 KDM4E (0.48) MAPK1HTTKMT2ALMNAALDH1A1
SCHEMBL2910342 0.75 HTT (0.41) MAPK1HTTMEN1KMT2ALMNA
SCHEMBL3202700 0.75 LMNA (0.40) MAPK1MEN1KMT2ALMNAALDH1A1
SCHEMBL2909821 0.73 LMNA (0.45) MAPK1HTTLMNAALDH1A1MAPT
SCHEMBL2907010 0.73 NPC1 (0.45) MAPK1HTTMEN1KMT2ALMNA
SCHEMBL2909964 0.73 PDE4A (0.37) HTTMEN1KMT2ALMNAALDH1A1
SCHEMBL2907448 0.72 TMPRSS15 (0.36) MAPK1MEN1KMT2ALMNAMAPT
SCHEMBL2909625 0.72 TP53 (0.47) MAPK1HTTMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1692109-B1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARM CORP (US) 2010-08-18 EP disclosed
EP-1692109-A2 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS Memory Pharmaceuticals Corporation (US) 2006-08-23 EP disclosed
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs MEMORY PHARMACEUTICAL CORPORATION 2005-10-06 US disclosed
WO-2005061458-A2 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARMACEUTICALS CORPORATION (US) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs PDE4A, PDE4B, PDE3B MAPK1 1430/4885HTT 4607/4885MEN1 2325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.